|
|
Wednesday, 24 December 2008
|
The FAS-II inhibitor triclosan has been widely used in antimicrobial creams, lotions and soaps and is often present as an additive in plastics, textiles and implantable medical devices. Earlier studies identified FabI, an enzyme in the FAS-II pathway, as the predicted target of triclosan in malaria parasites, propelling extensive research efforts to develop novel antimalarials based on this compound.
The research is published by Cell Press in the December 11th issue of the journal Cell Host and Microbe. |
|
Wednesday, 24 December 2008
|
An investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ALN-VSP, an RNAi therapeutic for the treatment of liver cancers, including hepatocellular carcinoma and other solid tumors with liver involvement has been submitted. ALN-VSP contains two small interfering RNAs (siRNAs), the molecules that mediate RNAi, formulated in a lipid nanoparticle developed by Tekmira Pharmaceuticals Corporation. ALN-VSP is designed to target two genes critical in the growth and development of cancer: kinesin spindle protein, or KSP, required for tumor proliferation; and vascular endothelial growth factor, or VEGF, required for tumor growth. |
|
Wednesday, 24 December 2008
|
The U.S. Food and Drug Administration would complete a review of a key diabetes drug candidate called alogliptin or SYR-322 by June 26, 2009. |
|
Wednesday, 24 December 2008
|
Last patient in for the phase II proof of concept clinical trial with DM-99, the third drug candidate to enter phase II human trials is announc
ed.
DM-99 behaves synergistically with GLP-1, which may significantly increase the value of DM-99 as GLP-1 analogs are a promising new class of drugs for type 2 diabetes. |
|
Tuesday, 23 December 2008
|
Positive results from a Phase IIa osteoarthritis (OA) study of the efficacy and safety of a next-generation NSAID, CG100649 were announced. The CG100649 treatment group met the primary efficacy endpoint by demonstrating a clinically and statistically significant change in the WOMAC(TM) OA score from baseline to Day 21 (p=0.010) compared to placebo. CG100649 is a first-in-class NSAID drug candidate with a new mode of "tissue-specific" activity which is designed to deliver sustained levels of drug to inflamed tissues while maintaining low systemic exposure by binding to carbonic anhydrase (CA) in red blood cells. Link: http://www.medicalnewstoday.com/articles/133629.phpSource:CrystalGenomics |
Tuesday, 23 December 2008
Last Updated ( Tuesday, 23 December 2008 )
|
Even a little bit of extra weight can raise the risk of heart failure, according to a U.S. study published that calculated the heart hazards of being pudgy but not obese. It is published in the journal Circulation. Source:Reuters |
|
Tuesday, 23 December 2008
|
A trial has found that it is safe to use artemisinin combination therapy (ACT) to treat pregnant women with malaria, but that efficacy is inferior to single-drug artesunate treatment. The study, published in next week's PLoS Medicine, suggests that the ACT evaluated in the trial, artemether-lumefantrine (AL), may have lower efficacy because drug concentrations were seen to be reduced during pregnancy. The authors suggest that longer, or more frequent, regimens of the drug combination should be evaluated for treatment of pregnant women. Link: http://www.eurekalert.org/pub_releases/2008-12/plos-ndr121608.phpSource:EurekAlert |
|
Tuesday, 23 December 2008
|
The pancreatic cancer treatment of FDA orphan drug status is the existing drug mibefradil, trade-named Posicor(tm). The T-channel-blocking drug was once marketed as a hypertension medication.Although it was withdrawn from the market due to drug-drug interactions with cholesterol-lowering medications, mibefradil has demonstrated efficacy in treating pancreatic cancer in animals and has also received FDA orphan drug status for the treatment of ovarian cancer. Further, because mibefradil is non-toxic, it could be an excellent alternative to existing cancer drugs. Link: http://www.newswise.com/articles/view/547673/?sc=rsmnSource:Newswise |
|
Tuesday, 23 December 2008
|
Leptin affects insulin release by indirectly inactivating osteocalcin. The work boosts researchers' hopes of using osteocalcin to treat diabetes-a possibility some drug companies have already started to investigate. The study will appear online December 22, 2008 and in the December 29, 2008 print issue of The Journal of Cell Biology (JCB). Link: http://www.physorg.com/news149168086.htmlSource:Physorg |
|
Tuesday, 23 December 2008
|
|
|
|
